# CorMedix inc. - NASDAQ:CRMD 

Story parrallel to suganmadex introduction 

Taurolock & Taurolidine 

Solving CRBST (catherer blood stream infection)

CRMD instead of using Citrate develloped their own solution.
Pairing Taurolidine with heparin making DefenCath 
DefenCath FDA approved in Nov 2023 
Target: Hospitals & dyalisis clinics 

Total Market potential more or less ~170,000 patient 
now around ~3000 patient 
already signed contracts for 70% TAM (?) 

looking at end 2027$ 

~250$ per vial 
CRBST cost around 63,000$ per case, nothing compared to 250$ 

NTAP end Nov 2026